Table 6.
Univariate and multivariate Fine-Gray models to assess risk factors for GNB PE-BSIs in allo-HSCT recipients
| Characteristic | Risk categories | Univariate analysis |
Multivariate analysis (n = 218, 55 GNB PE-BSI, 5 competing events) |
||
|---|---|---|---|---|---|
| Unadjusted HR of GNB PE-BSI (95% CI) | P value | AHR of GNB PE-BSI (95% CI) | P value | ||
| Age at allo-HSCT | Per 5-y older | 1.08 (0.98-1.18) | .107 | 1.11 (1.00-1.24) | .061 |
| Use of prophylaxis | Yes vs no | 0.37 (0.18-0.74) | .005 | 0.40 (0.19-0.83) | .013 |
| ANC ≤500 for ≥ 7 d before allo-HSCT | Yes vs no | 2.67 (1.33-5.36) | .006 | 2.52 (1.27-4.98) | .008 |
| Acute leukemia | Yes vs no | 1.44 (0.75-2.76) | .275 | Not included | - |
| MDR-GNB rectal carrier within 30 d before allo-HSCT | Yes vs no | 1.39 (0.41-4.71) | .599 | Not included | - |
| Conditioning regimen | RTC vs MAC | 1.07 (0.63-1.83) | .793 | 0.70 (0.38-1.28) | .251 |
| GVHD prophylaxis | PT-Cy/ATG or ATG-based regimens vs PT-Cy/sirolimus–based regimens | 1.03 (0.34-3.07) | .963 | Not included | - |
| Other regimens vs PT-Cy/sirolimus–based regimens |
0.61 (0.20-1.93) | .404 | |||
| Type of donor | Haploidentical vs MRD | 0.78 (0.38-1.61) | .497 | 0.91 (0.41-2.03) | .817 |
| CB vs MRD | 1.26 (0.37-4.30) | .139 | 1.63 (0.46-5.74) | .447 | |
| MUD vs MRD | 0.85 (0.43-1.68) | .645 | 0.81 (0.39-1.71) | .587 | |
| Disease phase at allo-HSCT | >CR1 vs CR1 | 0.41 (0.16-1.04) | .059 | Not included | - |
| AD/PR vs CR1 | 1.36 (0.77-2.38) | .287 | |||
| Upfront vs CR1 | 1.13 (0.37-3.44) | .824 | |||
| GNB BSI within 90 d before allo-HSCT | Yes vs no | 2.35 (1.25-4.43) | .008 | 2.15 (1.15-4.02) | .016 |
Bold values represent P values that reach statistical significance (P < 0.05). AD, advanced disease; ATG, antithymocyte globulin; CB, cord blood; CR, complete remission; MAC, myeloablative conditioning; MRD, match-related donor; MUD, match-unrelated donor; PR, partial response; PT-Cy, posttransplant cyclophosphamide; RTC, reduced toxicity conditioning.